董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bruno Baillavoine | 男 | Independent Director | 73 | 8.53万美元 | 1.74 | 2026-08-14 |
| Geert R. Kersten | 男 | Director, Chief Executive Officer and Treasurer | 68 | 96.99万美元 | 64.20 | 2026-08-14 |
| Robert Watson | 男 | Independent Director | 69 | 9.03万美元 | 2.02 | 2026-08-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Geert R. Kersten | 男 | Director, Chief Executive Officer and Treasurer | 68 | 96.99万美元 | 64.20 | 2026-08-14 |
| Patricia B. Prichep | 女 | Chief Financial and Operations Officer and Corporate Secretary | 75 | 40.62万美元 | 6.02 | 2026-08-14 |
| Eyal Talor | 男 | Chief Scientific Officer | 70 | 47.88万美元 | 5.71 | 2026-08-14 |
| John Cipriano | 男 | Senior Vice President of Regulatory Affairs | 84 | 30.64万美元 | 2.51 | 2026-08-14 |
董事简历
中英对照 | 中文 | 英文- Bruno Baillavoine
-
Bruno Baillavoine2015年6月加入CEL-SCI公司董事会。2010年以来，Baillavoine先生一直是Globomass Holdings Limited的合伙人，这是一家总部设在英格兰伦敦，从概念到最终运营可再生能源项目的开发商。自2012年起，Baillavoine先生一直担任Globomass Holdings的执行主席。Globomass Holdings在爱尔兰、保加利亚、克罗地亚、塞尔维亚都有子公司，并于最近收购了一家美国可再生能源公司20的股份。 1978年至1982年间，他是Ravenhead Ltd.的市场部经理，一家玻璃餐具的生产商和United Distillers Group（后来被Grand Metropolitan收购）。在此期间Baillavoine先生成为英国业务经理，在那里他恢复了United Distillers的市场份额和利润。1982年至1986年，Baillavoine先生是Prontaprint集团企业规划和集团营销总监，在那里他在4年内扩大了500个店铺。 1986至1988年，Baillavoine先生加入Grand Metropolitan Plc（现在的 Diageo Plc），一家富时100指数饮料、食品、酒店及休闲服务业集团，在特殊运营部门担任董事。在这个职位上，他为20000多个大蛋氨酸零售网点Grand Met‘s的故障排除部门开发计划。1988- 1991年，他是Nutri Systems （UK） Ltd.的董事总经理，这是一家美国专业监督减肥计划的子公司。 1991年至1995年，Baillavoine先生是BET Group plc（一家支持服务集团的跨国企业）的董事，并于1992年晋升为制造业务的董事总经理。在他任职期间BET的23亿欧元周转是FTSE 前100的公司最成功的周转之一。自1995年以来，Baillavoine先生曾在多个行业和地区担任多个首席执行官职位。 Baillavoine先生在欧洲和美国受教育（1972- 1976年在美国高中和University of Wisconsin Eau Claire）。
Bruno Baillavoine joined CEL SCI's Board of Directors in June 2015. Since February 2017, Mr. Baillavoine has been the Managing Director of Monty C Limited, based in London, UK, which provides advice to primarily international public company boards. Mr. Baillavoine joined ESG.AI Inc's Board of Directors, in November 2022. ESG.AI is a Canadian company. Mr. Baillavoine has been a consultant to Homerun Resources Inc. (a Canadian listed Company), since October 2024. From May 2017 to October 2024. Mr. Baillavoine was the Managing Director of Périclès Group UK Limited.He was an advisor to the Board of CSL Inc., now "Combat Sport Entertainment", a US Mixed Martial Arts company from 2017 to 2022.From July 2023 to October 2024, Mr. Baillavoine was Executive Chair of Gratomic Inc., a Canadian Graphite mining company listed on the TSXV. Between 2010 2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects. He became Executive Chairmans from 2012 to 2016. Globomass was acquired by CleanBay Inc. in 2016. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan).From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986 1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division.From 1988 1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses.Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972 1976). - Bruno Baillavoine2015年6月加入CEL-SCI公司董事会。2010年以来，Baillavoine先生一直是Globomass Holdings Limited的合伙人，这是一家总部设在英格兰伦敦，从概念到最终运营可再生能源项目的开发商。自2012年起，Baillavoine先生一直担任Globomass Holdings的执行主席。Globomass Holdings在爱尔兰、保加利亚、克罗地亚、塞尔维亚都有子公司，并于最近收购了一家美国可再生能源公司20的股份。 1978年至1982年间，他是Ravenhead Ltd.的市场部经理，一家玻璃餐具的生产商和United Distillers Group（后来被Grand Metropolitan收购）。在此期间Baillavoine先生成为英国业务经理，在那里他恢复了United Distillers的市场份额和利润。1982年至1986年，Baillavoine先生是Prontaprint集团企业规划和集团营销总监，在那里他在4年内扩大了500个店铺。 1986至1988年，Baillavoine先生加入Grand Metropolitan Plc（现在的 Diageo Plc），一家富时100指数饮料、食品、酒店及休闲服务业集团，在特殊运营部门担任董事。在这个职位上，他为20000多个大蛋氨酸零售网点Grand Met‘s的故障排除部门开发计划。1988- 1991年，他是Nutri Systems （UK） Ltd.的董事总经理，这是一家美国专业监督减肥计划的子公司。 1991年至1995年，Baillavoine先生是BET Group plc（一家支持服务集团的跨国企业）的董事，并于1992年晋升为制造业务的董事总经理。在他任职期间BET的23亿欧元周转是FTSE 前100的公司最成功的周转之一。自1995年以来，Baillavoine先生曾在多个行业和地区担任多个首席执行官职位。 Baillavoine先生在欧洲和美国受教育（1972- 1976年在美国高中和University of Wisconsin Eau Claire）。
- Bruno Baillavoine joined CEL SCI's Board of Directors in June 2015. Since February 2017, Mr. Baillavoine has been the Managing Director of Monty C Limited, based in London, UK, which provides advice to primarily international public company boards. Mr. Baillavoine joined ESG.AI Inc's Board of Directors, in November 2022. ESG.AI is a Canadian company. Mr. Baillavoine has been a consultant to Homerun Resources Inc. (a Canadian listed Company), since October 2024. From May 2017 to October 2024. Mr. Baillavoine was the Managing Director of Périclès Group UK Limited.He was an advisor to the Board of CSL Inc., now "Combat Sport Entertainment", a US Mixed Martial Arts company from 2017 to 2022.From July 2023 to October 2024, Mr. Baillavoine was Executive Chair of Gratomic Inc., a Canadian Graphite mining company listed on the TSXV. Between 2010 2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects. He became Executive Chairmans from 2012 to 2016. Globomass was acquired by CleanBay Inc. in 2016. Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan).From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986 1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division.From 1988 1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs. Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses.Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations. Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972 1976).
- Geert R. Kersten
-
Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
Geert R. Kersten has served in his current leadership role at CEL SCI since 1995. Mr. Kersten has been with CEL SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. - Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
- Geert R. Kersten has served in his current leadership role at CEL SCI since 1995. Mr. Kersten has been with CEL SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.
- Robert Watson
-
Robert Watson，他拥有20年以上的经验，担任首席执行官兼大型营利科技企业的董事会董事。他一直担任一些公司的首席执行官，其中包括Mayne Nickless Computer Services、Data Sciences International （位于英国）、 Lend Lease Employer Systems公司。此外，他曾创立并开发一些信息技术产业的成功企业，其中包括ICON，这是澳大利亚公认的两倍增长最快的两个私人公司。他是SEEK Limited公司（在线就业分类企业，在澳大利亚证券交易所上市），以及一些私人公司的董事。他曾担任Cytopia Limited公司的执行主席（从2004年11月23日到2006年11月22日），随后担任Cytopia公司的非执行主席，直到2010年1月收购Cytopia YM公司。他也曾担任Cytopia公司的提名与薪酬委员会主席，以及审计和风险委员会的成员。
Robert Watson has been a director of CEL SCI since December 2017. Mr. Watson currently is the Executive Chairperson and CEO of Health Gorilla. Mr. Watson was the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) from July 2017 to July 2023. He is a Director of Juvare, LLC. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 40 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold five companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. - Robert Watson，他拥有20年以上的经验，担任首席执行官兼大型营利科技企业的董事会董事。他一直担任一些公司的首席执行官，其中包括Mayne Nickless Computer Services、Data Sciences International （位于英国）、 Lend Lease Employer Systems公司。此外，他曾创立并开发一些信息技术产业的成功企业，其中包括ICON，这是澳大利亚公认的两倍增长最快的两个私人公司。他是SEEK Limited公司（在线就业分类企业，在澳大利亚证券交易所上市），以及一些私人公司的董事。他曾担任Cytopia Limited公司的执行主席（从2004年11月23日到2006年11月22日），随后担任Cytopia公司的非执行主席，直到2010年1月收购Cytopia YM公司。他也曾担任Cytopia公司的提名与薪酬委员会主席，以及审计和风险委员会的成员。
- Robert Watson has been a director of CEL SCI since December 2017. Mr. Watson currently is the Executive Chairperson and CEO of Health Gorilla. Mr. Watson was the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) from July 2017 to July 2023. He is a Director of Juvare, LLC. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 40 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold five companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University.
高管简历
中英对照 | 中文 | 英文- Geert R. Kersten
Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
Geert R. Kersten has served in his current leadership role at CEL SCI since 1995. Mr. Kersten has been with CEL SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.- Geert R. Kersten自1995年 CEL-SCI公司担任领导职务。Mr. Kersten自1987年毕业的早些时候就在CEL-SCI工作。他在癌症领域首创免疫疗法，领先20年，成功领导CEL-SCI在生物产业攻克了很多难题。在加入CEL-SCI之前， Mr. Kersten在Finley & Kumble律师事务所和Source Capital公司工作，该公司是位于弗吉尼亚州麦克莱恩的投资银行。他是德国人，毕业于英格兰的米尔菲尔德中学，在美国完成学业。Mr. Kersten获得审计学士学位，乔治华盛顿大学获得工商管理硕士，华盛顿特区美国大学获得法学博士。
- Geert R. Kersten has served in his current leadership role at CEL SCI since 1995. Mr. Kersten has been with CEL SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.
- Patricia B. Prichep
Patricia B. Prichep于1992年加入CEL-SC，1994年3月担任CEL-SCI运营高级副总裁。在1992年12月至1994年3月，Ms. Prichep担任CEL-SCI运营主管。Ms. Prichep于2000年5月担任CEL-SCI的法团秘书。她负责CEL-SCI的所有日常营运事宜，包括：人力资源， 与CEL-SCI的独立注册公共会计公司联络财务报表。从1990年6月至1992年12月，Ms. Prichep担任质管经理和全国证券交易商协会产品、系统、支持竞标部门的管理。她负责内部审计和工作流程分析的操作。在1982年至1990年，Ms. Prichep担任Source Capital有限公司副总裁何运营经理。
Patricia B. Prichep has over 35 years of experience in business operations and administration. She assumed the duties of CEL SCI's Chief Financial and Operations Officer, effective November 2024. She joined CEL SCI in 1992 and was CEL SCI's Senior Vice President of Operations from March 1994 to October 2024. Between December 1992 and March 1994, Ms. Prichep was CEL SCI's Director of Operations. Ms. Prichep became CEL SCI's Corporate Secretary in May 2000. She is responsible for all day to day operations of CEL SCI, including human resources and is the liaison with CEL SCI's independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD's Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.- Patricia B. Prichep于1992年加入CEL-SC，1994年3月担任CEL-SCI运营高级副总裁。在1992年12月至1994年3月，Ms. Prichep担任CEL-SCI运营主管。Ms. Prichep于2000年5月担任CEL-SCI的法团秘书。她负责CEL-SCI的所有日常营运事宜，包括：人力资源， 与CEL-SCI的独立注册公共会计公司联络财务报表。从1990年6月至1992年12月，Ms. Prichep担任质管经理和全国证券交易商协会产品、系统、支持竞标部门的管理。她负责内部审计和工作流程分析的操作。在1982年至1990年，Ms. Prichep担任Source Capital有限公司副总裁何运营经理。
- Patricia B. Prichep has over 35 years of experience in business operations and administration. She assumed the duties of CEL SCI's Chief Financial and Operations Officer, effective November 2024. She joined CEL SCI in 1992 and was CEL SCI's Senior Vice President of Operations from March 1994 to October 2024. Between December 1992 and March 1994, Ms. Prichep was CEL SCI's Director of Operations. Ms. Prichep became CEL SCI's Corporate Secretary in May 2000. She is responsible for all day to day operations of CEL SCI, including human resources and is the liaison with CEL SCI's independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD's Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.
- Eyal Talor
Eyal Talor博士。1993年10月加入CEL-SCI。2009年10月，他被提升为首席科学官。在此晋升之前，他是研究和制造高级副总裁。他是一名临床免疫学家，在免疫治疗应用的临床研究和药物开发方面拥有超过27年的实践管理经验；生物制药行业的临床前至III期临床试验。他的专长包括生物制药研发和生物制品开发，GMP（良好生产规范）制造，质量控制测试以及GMP生产和测试设施的设计和建设。他曾担任临床实验室主任（由马里兰州认证），并在临床前和临床试验（I - III期）和GCP（良好临床实践）要求的设计方面拥有经验。他在FDA/GMP、USP和ICH指导方针下的生物测定开发、分析方法验证、原材料规格和QC（质量控制）测试开发的不同方面也拥有丰富的经验。他在IND和其他监管提交文件的准备方面拥有丰富的经验。他的科学专业领域包括免疫反应评估。他是超过25篇出版物的作者，并发表了一些关于临床免疫学的免疫调节的评论。在加入CEL-SCI之前，他曾担任CBL， Inc.的研发和临床开发总监，SRA Technologies, Inc.的首席科学家-项目总监和临床实验室总监。在此之前，他是The Johns Hopkins University， Medical Institutions的全职教员；公共卫生学院。他发明的技术已获得10项已颁发的专利，包括cell - sci Corporation e在癌症中的Multikine的物质组成和方法，以及两项平台肽技术，抗原定向t细胞凋亡（“Adapt”）和LEAPS，用于治疗自身免疫性疾病，哮喘，过敏，移植排斥和传染病。他还负责许多产品和工艺发明以及许多未决的美国和PCT专利申请。他在加拿大安大略省渥太华大学获得微生物学和免疫学博士学位，并在美国马里兰州巴尔的摩市约翰霍普金斯大学接受临床和细胞免疫学博士后培训。他在约翰霍普金斯大学医学机构担任助理教学职位。
Eyal Talor joined CEL SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 30 years of hands on management of clinical research and drug development for immunotherapy application; pre clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw materials, product intermediates and finished product specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine's composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T cells ('Adapt') and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He also holds a facility teaching position at the Johns Hopkins University Medical Institutions.- Eyal Talor博士。1993年10月加入CEL-SCI。2009年10月，他被提升为首席科学官。在此晋升之前，他是研究和制造高级副总裁。他是一名临床免疫学家，在免疫治疗应用的临床研究和药物开发方面拥有超过27年的实践管理经验；生物制药行业的临床前至III期临床试验。他的专长包括生物制药研发和生物制品开发，GMP（良好生产规范）制造，质量控制测试以及GMP生产和测试设施的设计和建设。他曾担任临床实验室主任（由马里兰州认证），并在临床前和临床试验（I - III期）和GCP（良好临床实践）要求的设计方面拥有经验。他在FDA/GMP、USP和ICH指导方针下的生物测定开发、分析方法验证、原材料规格和QC（质量控制）测试开发的不同方面也拥有丰富的经验。他在IND和其他监管提交文件的准备方面拥有丰富的经验。他的科学专业领域包括免疫反应评估。他是超过25篇出版物的作者，并发表了一些关于临床免疫学的免疫调节的评论。在加入CEL-SCI之前，他曾担任CBL， Inc.的研发和临床开发总监，SRA Technologies, Inc.的首席科学家-项目总监和临床实验室总监。在此之前，他是The Johns Hopkins University， Medical Institutions的全职教员；公共卫生学院。他发明的技术已获得10项已颁发的专利，包括cell - sci Corporation e在癌症中的Multikine的物质组成和方法，以及两项平台肽技术，抗原定向t细胞凋亡（“Adapt”）和LEAPS，用于治疗自身免疫性疾病，哮喘，过敏，移植排斥和传染病。他还负责许多产品和工艺发明以及许多未决的美国和PCT专利申请。他在加拿大安大略省渥太华大学获得微生物学和免疫学博士学位，并在美国马里兰州巴尔的摩市约翰霍普金斯大学接受临床和细胞免疫学博士后培训。他在约翰霍普金斯大学医学机构担任助理教学职位。
- Eyal Talor joined CEL SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 30 years of hands on management of clinical research and drug development for immunotherapy application; pre clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw materials, product intermediates and finished product specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine's composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T cells ('Adapt') and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He also holds a facility teaching position at the Johns Hopkins University Medical Institutions.
- John Cipriano
John Cipriano于2004年3月至2008年12月、2009年10月再次担任 CEL-SCI法规事务高级副总裁。此外，他在美国食品药品监管局担任众多职务，包括，生物制剂新药临床实验部门、I生物研究办公室副局长、IND分部生物制品评价办公室、生物学办公室副主管。 Mr. Cipriano在波士顿麻省理工大学药学院获得药理学学士学位， 印第安纳州拉菲特西部普渡大学生物化学制药理科硕士学位。
John Cipriano was CEL SCI's Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano received his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.- John Cipriano于2004年3月至2008年12月、2009年10月再次担任 CEL-SCI法规事务高级副总裁。此外，他在美国食品药品监管局担任众多职务，包括，生物制剂新药临床实验部门、I生物研究办公室副局长、IND分部生物制品评价办公室、生物学办公室副主管。 Mr. Cipriano在波士顿麻省理工大学药学院获得药理学学士学位， 印第安纳州拉菲特西部普渡大学生物化学制药理科硕士学位。
- John Cipriano was CEL SCI's Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano received his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.